Danicamtiv

Add links
Source: Wikipedia, the free encyclopedia.
Danicamtiv
Clinical data
Other namesMYK-491
Legal status
Legal status
  • Investigational
Identifiers
  • 4-[(1R)-1-[3-(Difluoromethyl)-1-methylpyrazol-4-yl]sulfonyl-1-fluoroethyl]-N-(1,2-oxazol-3-yl)piperidine-1-carboxamide
JSmol)
  • C[C@@](C1CCN(CC1)C(=O)NC2=NOC=C2)(F)S(=O)(=O)C3=CN(N=C3C(F)F)C
  • InChI=1S/C16H20F3N5O4S/c1-16(19,29(26,27)11-9-23(2)21-13(11)14(17)18)10-3-6-24(7-4-10)15(25)20-12-5-8-28-22-12/h5,8-10,14H,3-4,6-7H2,1-2H3,(H,20,22,25)/t16-/m1/s1
  • Key:NREKKBAMVWQRES-MRXNPFEDSA-N

Danicamtiv is a cardiac myosin activator developed by Bristol Myers Squibb to treat dilated cardiomyopathy.[1][2][3][4]

References

  1. S2CID 263759444
    .
  2. PMID 34096321
    .
  3. S2CID 259995078
    .
  4. S2CID 224812191
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Danicamtiv&oldid=1201213641"